Upcoming Presentations, Milestone Payments, Quarterly Financial Results, and New Appointments Today, Analysts' Corner announced new research reports highlighting Medivation, Inc. (NASDAQ: MDVN), Acceleron Pharma, Inc. (NASDAQ: XLRN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Arrowhead Research Corp. (NASDAQ: ARWR), and Oxford Immunotec Global PLC (NASDAQ: OXFD). Medivation, Inc. On December 19, 2013, Medivation, Inc. (Medivation) and Astellas Pharma Global Development, Inc. announced that additional data from the Phase 3 PREVAIL trial evaluating enzalutamide in patients with chemotherapy-naïve metastatic prostate cancer will be highlighted in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2014 Genitourinary (GU) Cancers Symposium in San Francisco. According to Medivation, Tomasz M. Beer, OHSU Knight Cancer Institute, Oregon Health and Science University, will lead the presentation on Thursday, January 30, 2014 from 7:45 a.m. to 9:45 a.m. Medivation also reported that two additional enzalutamide abstracts will be presented during the General Poster Sessions on January 30, 2014 from 11:30 a.m. to 1:00 p.m., and on January 31, 2014 from 12:00 to 1:30 p.m. The Full Research Report on Medivation, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Acceleron Pharma, Inc. On December 18, 2013, Acceleron Pharma, Inc. (Acceleron) announced that Celgene, its collaboration partner, has initiated a phase 2 clinical trial of sotatercept in patients with end stage renal disease on hemodialysis. Acceleron reported that Sotatercept is a novel and first-in-class activin type IIA receptor (ActRIIA) fusion protein that acts during late-stage erythropoiesis (red blood cell production) to increase the production of mature red blood cells into circulation. The Company stated that it will receive a $7 million milestone payment from Celgene for the achievement of this event and is also eligible to receive future development, regulatory, and commercial milestones of up to $360 million for the sotatercept program. Matthew Sherman, M.D., Chief Medical Officer at Acceleron, said, "We believe that the distinct profile of sotatercept could benefit many patients, including those who have end stage renal disease, the most advanced stage of chronic kidney disease. We look forward to the ongoing development of this promising protein therapeutic candidate, which is also being studied in phase 2 trials in several rare hematologic diseases, including beta-thalassemia and myelodysplastic syndromes. The Full Research Report on Acceleron Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Aerie Pharmaceuticals, Inc. On December 4, 2013, Aerie Pharmaceuticals, Inc. (Aerie) released its Q3 2013 results. Aerie registered net loss attributable to common shareholders of $10.9 million in Q3 2013, compared to net loss attributable to common shareholders of $3.7 million in Q3 2012. The Company posted basic and diluted loss per share of $10.81 in Q3 2013, compared to basic and diluted loss per share of $3.87 in Q3 2012. Commenting on the results, Vicente Anido, Ph.D., Aerie Chairman and CEO, said, "Aerie made significant progress in 2013, capped off with our successful IPO which provides the capital for us to continue to fund development of our highly differentiated product portfolio." Anido continued, "We are currently preparing for our dual-action AR-13324 Phase 3 registration trials, which are expected to commence in the summer of 2014, and our Phase 2b clinical trial for triple-action PG324, which is expected to commence early in the first quarter of 2014." The Full Research Report on Aerie Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Arrowhead Research Corp. Research Report On December 18, 2013, Arrowhead Research Corp. (Arrowhead) released its Q4 FY 2013 and full-year FY 2013 results (period ended September 30, 2013). Arrowhead registered net loss attributable to the Company of $31.1 million in full-year FY 2013, compared to net loss attributable to the Company of $21.1 million in full-year FY 2012. Arrowhead posted basic and diluted loss per share of $1.30 in full-year FY 2013, compared to basic and diluted loss per share of $1.90 in full-year FY 2012. According to the Company, it closed a $60 million financing from a syndicate of high-quality biotech investors during Q4 FY 2013, which provided sufficient capital to fund development into 2016. The Full Research Report on Arrowhead Research Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Oxford Immunotec 7